{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-277511","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2026-06-22T20:05:14+00:00","discovered_at":"2026-06-22T20:06:00.293382+00:00","generated_at":"2026-06-22T20:07:10.701057+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ORIC shareholders approve amended equity plan, elect two Class III directors at annual meeting","bullets":["Shareholders approved amended 2020 Equity Incentive Plan (61.2M for, 27.3M against); annual share increase cut from 5% to 4% of outstanding, evergreen cap removed.","Jacob Chacko, M.D. and Mardi C. Dier elected as Class III directors; Chacko received 89.3M for, Dier 82.0M for.","KPMG ratified as independent auditor for FY2026 with 94.5M votes in favor; advisory say-on-pay passed with 88.5M for.","Advisory vote favored annual frequency of future say-on-pay votes (89.4M for one year); next frequency vote by 2032.","Turnout of 91.4% of outstanding shares; plan amendment saw 27.3M against, reflecting notable shareholder dissent."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-277511","json":"https://secwatch.observer/filing/0001193125-26-277511.json","markdown":"https://secwatch.observer/filing/0001193125-26-277511.md","text":"https://secwatch.observer/filing/0001193125-26-277511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526277511/0001193125-26-277511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526277511/d103876d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T20:07:10.701057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b3defd0dd2c1e926dcd27811aff4518309ddff6","claim":"Oric Pharmaceuticals, Inc. shareholders approved Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2026-06-18 meeting.","evidence_excerpt":"Proposal 4 - Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory (non-binding) basis, executive compensation. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 88,453,809 1,250,074 2,373 4,865,025","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526277511/0001193125-26-277511-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"},{"claim_id":"2d6629b5c683a0d37eb4101589886e53451639cc","claim":"Oric Pharmaceuticals, Inc. shareholders approved Approval of the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as Amended and Restated at the 2026-06-18 meeting.","evidence_excerpt":"Proposal 3 - Approval of the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as Amended and Restated The Company’s stockholders approved the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as amended and restated. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 61,228,918 27,264,875 1,212,463 4,865,025","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526277511/0001193125-26-277511-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"},{"claim_id":"b777421c232188fccd8a5f283f493ae8d30b3cc9","claim":"Oric Pharmaceuticals, Inc. shareholders approved Advisory Vote on the Frequency of Future Stockholder Advisory Votes on the Compensation of the Company’s Named Executive Officers at the 2026-06-18 meeting.","evidence_excerpt":"Proposal 5 - Advisory Vote on the Frequency of Future Stockholder Advisory Votes on the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory (non-binding) basis, for the frequency of future stockholder advisory votes regarding executive compensation to be held every one year. In accordance with the recommendation of the Company’s board of directors and the voting results of the Company’s stockholders on this non-binding, advisory vote, the Company will hold an advisory (non-binding) vote on the compensation of the Company’s named executive officers on an annual basis. The next non-binding, advisory vote on the frequency of future stockholder advisory votes on the compensation of the Company’s named execute officers will take place no later than the Company’s annual meeting of stockholders in 2032. The tabulation of votes on this matter was as follows: For One Year For Two Years For Three Years Abstain Broker Non-Votes 89,392,979 6,9","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526277511/0001193125-26-277511-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"},{"claim_id":"bcd1d4c57dd3a358dd46df6d181041dc2a8522ad","claim":"Oric Pharmaceuticals, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-18 meeting.","evidence_excerpt":"Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 94,536,096 34,641 544 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526277511/0001193125-26-277511-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"},{"claim_id":"dae14af01605d80e75fc611b27a8b49220129628","claim":"Oric Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.","evidence_excerpt":"Proposal 1 - Election of Directors The Company’s stockholders elected each of the following nominees to serve as a Class III director, to hold office until the Company’s 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier death, resignation or removal. The tabulation of votes on this matter was as follows: Nominees For Withheld Broker Non-Votes Jacob M. Chacko, M.D. 89,298,150 408,106 4,865,025 Mardi C. Dier 82,007,899 7,698,357 4,865,025","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526277511/0001193125-26-277511-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}